Tyra Biosciences to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Tyra Biosciences (Nasdaq: TYRA), a clinical-stage biotechnology firm, announced its participation in key investor conferences. CEO Todd Harris will engage in a fireside chat at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, at 2:15 PM ET. He will also present at the Bank of America 2023 Healthcare Conference on May 11, 2023, at 9:35 AM PT. TYRA focuses on developing precision medicines targeting FGFR biology and utilizes its innovative SNÅP platform for drug design. For live updates and webcasts, visit the company's investor page.

News Market Reaction – TYRA

-3.21%

-3.21% Session move

In the trading session that priced this news, TYRA declined 3.21%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

CARLSBAD, Calif., March 29, 2023 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today announced that management will present and participate in the following investor conferences:

Cantor's The Future of Oncology Virtual Symposium 

• Todd Harris, CEO of TYRA, will participate virtually in a fireside chat on Tuesday, April 4, 2023, at 2:15 pm ET 

Bank of America 2023 Healthcare Conference

• Mr. Harris will present on Thursday, May 11, 2023, at 9:35 am PT

A live and archived webcast of the Bank of America event will be available via the For Investors page on the Investor section of the TYRA website. 

About Tyra Biosciences

Tyra Biosciences, Inc. (Nasdaq: TYRA) is a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in FGFR biology. The Company's in-house precision medicine platform, SNÅP, enables rapid and precise drug design through iterative molecular SNÅPshots that help predict genetic alterations most likely to cause acquired resistance to existing therapies. TYRA's initial focus is on applying its accelerated small molecule drug discovery engine to develop therapies in targeted oncology and genetically defined conditions. TYRA is based in Carlsbad, CA. For more information about our science, pipeline and people, please visit www.tyra.bio and engage with us on LinkedIn. 

Contact:

Amy Conrad
aconrad@tyra.bio

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/tyra-biosciences-to-participate-in-upcoming-investor-conferences-301785119.html

SOURCE Tyra Biosciences

FAQ

When will Tyra Biosciences present at investor conferences?

Tyra Biosciences will present at Cantor's The Future of Oncology Virtual Symposium on April 4, 2023, and at the Bank of America 2023 Healthcare Conference on May 11, 2023.

Who is the CEO of Tyra Biosciences?

The CEO of Tyra Biosciences is Todd Harris.

What is Tyra Biosciences' focus?

Tyra Biosciences focuses on developing next-generation precision medicines targeting FGFR biology.

What is the SNÅP platform?

The SNÅP platform is Tyra's precision medicine tool for rapid and precise drug design.

Where can I watch the presentations by Tyra Biosciences?

Live and archived webcasts of the presentations can be accessed on Tyra Biosciences' Investor page.